KIROMIC BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.19 USD | +6.83% |
|
-12.75% | +151.72% |
| 06-20 | Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial | CI |
| 06-07 | Kiromic Biopharma, Inc. Issues 25% Senior Secured Convertible Promissory Note | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 62.11 | 23.62 | 3.297 | 1.095 |
| Enterprise Value (EV) 1 | 52.43 | -1.28 | 12.06 | 13.43 |
| P/E ratio | -1.92 x | -0.68 x | -0.08 x | -0.04 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -2.76 x | 0.05 x | -0.41 x | -0.76 x |
| EV / FCF | -320 x | 0.1 x | -0.78 x | -0.94 x |
| FCF Yield | -0.31% | 989% | -128% | -106% |
| Price to Book | 5.47 x | 0.87 x | -0.61 x | -0.12 x |
| Nbr of stocks (in thousands) | 244 | 515 | 608 | 1,258 |
| Reference price 2 | 254.1 | 45.90 | 5.421 | 0.8700 |
| Announcement Date | 31/03/21 | 08/04/22 | 17/04/23 | 19/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -3.102 | -3.618 | -19 | -24.84 | -29.44 | -17.72 |
| EBIT 1 | -3.183 | -3.705 | -19.2 | -25.31 | -31.11 | -19.94 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.816 | -3.728 | -19.2 | -25.59 | -34.73 | -20.95 |
| Net income 1 | -3.816 | -3.728 | -19.2 | -25.59 | -34.73 | -20.95 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -40.00 | -41.69 | -132.6 | -67.82 | -64.42 | -21.41 |
| Free Cash Flow 1 | -1.476 | -1.895 | -0.1636 | -12.66 | -15.46 | -14.23 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 15/11/19 | 11/05/20 | 31/03/21 | 08/04/22 | 17/04/23 | 19/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT | - | - | - | - |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS 2 | - | - | - | -22.50 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 08/04/22 | 13/05/22 | 12/08/22 | 14/11/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 8.77 | 12.3 |
| Net Cash position 1 | 0.38 | 1.93 | 9.68 | 24.9 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.2977 x | -0.6964 x |
| Free Cash Flow 1 | -1.48 | -1.89 | -0.16 | -12.7 | -15.5 | -14.2 |
| ROE (net income / shareholders' equity) | 152% | -332% | -288% | -132% | -322% | 281% |
| ROA (Net income/ Total Assets) | -156% | -131% | -155% | -72.6% | -91.1% | -103% |
| Assets 1 | 2.453 | 2.84 | 12.39 | 35.24 | 38.13 | 20.29 |
| Book Value Per Share 2 | -88.70 | -88.70 | 46.50 | 52.90 | -8.910 | -7.250 |
| Cash Flow per Share 2 | 4.030 | 20.20 | 41.50 | 49.10 | 1.000 | 2.550 |
| Capex 1 | 0.14 | 0.3 | 1.46 | 1.89 | 4.88 | 0.21 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 15/11/19 | 11/05/20 | 31/03/21 | 08/04/22 | 17/04/23 | 19/03/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +151.72% | 3.38M | |
| +15.20% | 121B | |
| +19.67% | 113B | |
| +18.95% | 26.02B | |
| -23.86% | 19.39B | |
| -19.03% | 15.91B | |
| -20.90% | 15.09B | |
| -46.14% | 15.06B | |
| +63.85% | 14.93B | |
| +4.49% | 13.85B |
- Stock Market
- Equities
- KRBP Stock
- Financials Kiromic BioPharma, Inc.
